Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.Financial_Report.xls
10-K - 2012 ANNUAL REPORT - Medical Information Technology, Inc.tenk.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R31.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R50.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R30.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R47.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R32.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R52.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R36.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R39.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R48.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R33.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R27.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R38.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R43.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R53.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R44.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R41.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R35.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R51.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R34.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R37.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R28.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R45.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R55.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R42.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R54.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R29.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R46.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R40.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Medical Information Technology, Inc.R49.htm
EX-32 - SECTION 1350 CERTIFICATIONS - Medical Information Technology, Inc.ex32.htm
EX-21 - SUBSIDIARIES OF THE COMPANY - Medical Information Technology, Inc.ex21.htm
EX-23 - CONSENT OF ERNST & YOUNG LLP - Medical Information Technology, Inc.ex23.htm
EX-31 - RULE 13A-14(A) CERTIFICATIONS - Medical Information Technology, Inc.ex31.htm
v2.4.0.6
Significant Accounting Policies:
12 Months Ended
Dec. 31, 2012
Significant Accounting Policies:
Note 1. Significant Accounting Policies:

MEDITECH is engaged in the development, manufacture, licensing and support of computer software products for the hospital market. The principal market for its products consists of health care providers located primarily in the United States and Canada.

The accompanying consolidated financial statements reflect the application of certain accounting policies discussed below. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The consolidated financial statements include MEDITECH’s wholly owned subsidiary, LSS Data Systems, Inc., in accordance with Accounting Standards Codification (ASC) 810, Consolidation of Financial Statements.

(a) Revenue Recognition

MEDITECH follows the provisions of ASC 985-605-25, Software Revenue Recognition, and ASC 605-35-25, Construction-Type and Production-Type Contracts. MEDITECH enters into perpetual software license contracts which provide for a customer deposit upon contract execution, milestone billings during the implementation phase and fixed monthly support fees thereafter.

MEDITECH classifies software fees and related implementation fees together as product revenue in the statement of income and recognizes these fees as revenue upon completion of each contract milestone. MEDITECH classifies post-implementation support fees as service revenue in the statement of income and recognizes these fees as revenue when the related services are rendered.

MEDITECH follows the provisions of ASC 605-45-15, Reimbursements Received for Out-of-Pocket Expenses. Such expenses are characterized as product revenue with offsetting operating expenses included in the consolidated income statement.

(b) Software Development Costs

MEDITECH follows the provisions of ASC 985-20, Accounting for the Costs of Computer Software to Be Sold, Leased or Marketed. ASC 985-20 establishes standards for capitalizing software development costs incurred after technological feasibility of the software development projects is established and the realizability of such capitalized costs through future operations is expected, if such costs become material. To date, development costs incurred by MEDITECH after technological feasibility has been established have been immaterial and as such have been charged to operations as incurred.

(c) Cash and Equivalents

MEDITECH considers all highly liquid investments purchased with original maturities of 90 days or less to be cash equivalents.

(d) Common Stock Dividend Policy

MEDITECH’s Board of Directors has full discretion regarding the timing and amounts of dividends paid on common stock.

(e) Fair Value of Financial Instruments and Concentration of Credit Risk

The carrying value of MEDITECH’s cash and cash equivalents, accounts receivable and accounts payable approximates their fair value due to the short-term nature of these financial instruments. MEDITECH’s marketable securities are carried at fair value.

Financial instruments that potentially subject MEDITECH to concentrations of credit risk are principally cash, cash equivalents, marketable securities and accounts receivable. MEDITECH places its cash and cash equivalents in highly rated institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom MEDITECH makes substantial sales. To reduce risk, MEDITECH routinely assesses the financial strength of its customers and, as a result, believes that its accounts receivable credit risk exposure is limited. MEDITECH maintains a reserve for doubtful accounts but historically has not experienced any significant credit losses related to an individual customer or groups of customers. As of December 31, 2010, 2011 and 2012 no individual customer accounted for greater than 10% of the outstanding accounts receivable.